Ironwood Pharmaceuticals, Inc.
IRWD
$3.73
$0.236.57%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 338.99M | 308.52M | 317.68M | 351.41M | 378.42M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 338.99M | 308.52M | 317.68M | 351.41M | 378.42M |
| Cost of Revenue | -5.21M | 2.15M | 9.17M | 7.55M | 26.77M |
| Gross Profit | 344.19M | 306.37M | 308.51M | 343.86M | 351.65M |
| SG&A Expenses | 96.55M | 110.76M | 130.93M | 144.27M | 157.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 195.22M | 216.78M | 243.97M | 255.69M | 283.06M |
| Operating Income | 143.77M | 91.74M | 73.71M | 95.72M | 95.36M |
| Income Before Tax | 93.57M | 42.91M | 23.97M | 65.20M | 71.56M |
| Income Tax Expenses | 65.02M | 50.80M | 56.31M | 64.32M | 74.68M |
| Earnings from Continuing Operations | 28.55 | -7.89 | -32.34 | 0.88 | -3.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | 658.00K |
| Net Income | 28.55M | -7.89M | -32.34M | 880.00K | -2.46M |
| EBIT | 143.77M | 91.74M | 73.71M | 95.72M | 95.36M |
| EBITDA | 145.68M | 93.68M | 75.69M | 97.73M | 97.40M |
| EPS Basic | 0.17 | -0.05 | -0.20 | 0.01 | -0.02 |
| Normalized Basic EPS | 0.44 | 0.24 | 0.18 | 0.27 | 0.27 |
| EPS Diluted | 0.15 | -0.06 | -0.21 | -0.01 | -0.03 |
| Normalized Diluted EPS | 0.41 | 0.23 | 0.18 | 0.27 | 0.27 |
| Average Basic Shares Outstanding | 644.36M | 641.85M | 639.14M | 635.87M | 632.43M |
| Average Diluted Shares Outstanding | 675.03M | 657.49M | 639.67M | 636.40M | 632.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |